Loading clinical trials...
Loading clinical trials...
A Phase I/II, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Transendocardial Injection of Autologous Human Cells (Mesenchymal or the Combination of MSC and Cardiac Stem Cells) in Patients With Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction.
Conditions
Interventions
Autologous hMSCs
Autologous Human C-Kit CSCs II
+2 more
Locations
1
United States
ISCI / University of Miami
Miami, Florida, United States
Start Date
March 1, 2025
Primary Completion Date
March 1, 2030
Completion Date
March 1, 2032
Last Updated
October 22, 2020
NCT05198791
NCT06744322
NCT07301034
NCT07257198
NCT06438315
NCT07444957
Lead Sponsor
Joshua M Hare
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions